ETTX - Zai Lab Entasis antibiotic meets primary endpoint in late-stage trial

SUL-DUR, an antibiotic from Zai Lab (NASDAQ:ZLAB) and Entasis Therapeutics (NASDAQ:ETTX), met its primary endpoint in a phase 3 trial evaluating efficacy in infections caused by Acinetobacter baumannii. That endpoint was 28-day all-cause mortality in patients demonstrating statistical non-inferiority versus colistin. SUL-DUR (sulbactam-durlobactam) mortality was 19% compared to 32.3% in those who were given colistin. Also, clinical cure the test-of-cure visit was 61.9% in SUL-DUR arm compared to 40.3% in the colistin arm. Last week, Zai Lab and Geneseeq inked a strategic collaboration in China.

For further details see:

Zai Lab, Entasis antibiotic meets primary endpoint in late-stage trial